Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Study of disease phenotype and its association with prognosis of paediatric inflammatory bowel disease in China

BMC Pediatrics201818:229

https://doi.org/10.1186/s12887-018-1212-x

  • Received: 28 April 2018
  • Accepted: 6 July 2018
  • Published:
Open Peer Review reports

Abstract

Background

To investigate the unique features of inflammatory bowel disease (IBD) in children, we wanted to identify whether there might be a strong correlation between the disease phenotype and its prognosis at various ages in paediatric patients.

Methods

We collected data from patients diagnosed with IBD (ulcerative colitis (UC) or Crohn’s disease (CD)) from 2002 to 2016. The diagnosis was made according to the Porto criteria and Paris Classification. Patient characteristics, clinical manifestations and treatments were collected. Risk factors for surgery, mortality and relapse were analysed by Cox proportional hazard models.

Results

Of the 143 patients, 113 had CD, and 30 had UC; there were 89 males and 54 females with a median age of 9 years (y). Thirteen patients in the 0–2 y group were identified as having mutations in IL-10 receptor A, and this mutation was significantly more common in this age group than in 3–9 and 10–16 y patients. The risk factor for surgery was the B3 phenotype; risk factors for death were age 0–2 y and B3 phenotype; 0–2 y, B3 phenotype and steroid dependency were risk factors for early relapse.

Conclusions

Clinical manifestations of the onset of IBD in infants and toddlers were extensive and aggressive and were closely associated with early relapse and death. It is of particular interest that some of these patients developed IBD due to monogenic disorders; thus, introduction of genetic testing is essential for these patients.

Keywords

  • Inflammatory bowel disease
  • Children
  • Infantile or toddler onset IBD
  • Paris classification
  • Prognosis

Background

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC); IBD-unclassified (IBD-U) is a group of chronic gastrointestinal inflammatory diseases. Approximately 25% of patients manifest with the disease in childhood or adolescence [1]. Our previous studies have indicated that the morbidity of paediatric IBD has been rapidly increasing in China over the past three decades [2]. Studies have also shown that paediatric IBD manifests as an extensive and aggressive disease [3, 4]. However, further study suggested that the clinical manifestations and prognosis varied greatly in patients with various onset ages [5]. In our study, the paediatric Paris classification released in 2013 was used, as it is valuable for paediatric IBD studies [6]. Using the Paris classification, we further sub-classified IBD patients into two groups, A1a (0–10 y) and A1b (10–17 y). We also focused on the children with very early onset IBD (VEO-IBD), including infantile and toddler onset IBD, as infantile IBD might be partially linked to monogenic diseases such as defects in IL-10 or its receptors, Wiskott-Aldrich Syndrome, XIAP deficiency, leukocyte adhesion deficiencies, CD40L deficiency, IPEX syndrome and several others [79]. The clinical manifestations and phenotypes in this group of patients were different from those of patients in other age groups. However, it remains controversial as to whether these patients with monogenic diseases phenotype should be classified as having IBD [9, 10].

Because the clinical manifestations and phenotypes vary in IBD children, the prognosis of IBD is remarkably different in patients of different ages, and there is a lack of long-term follow-up studies on the natural course of the disease. In the current study, the natural course of disease was recorded with long-term follow-up to define the features and progression of paediatric IBD in China.

Methods

Medical records were retrospectively selected from the Department of Paediatrics, Ruijin hospital and North Ruijin Hospital; patients were diagnosed as having UC, CD, or IBD-U from January 2002 to September 2016. As a paediatric IBD centre, patients suspected of having IBD were recorded and followed up. The diagnosis was confirmed by at least three gastrointestinal (GI) paediatricians after complete physical examination, endoscopy, pathological examination, and radiological imaging determinations. The diagnosis was made according to the Porto criteria and Paris classification [6, 11, 12]. Complex patients with unclear diagnosis were re-evaluated by a multi-disciplinary team (MDT) of IBD professionals, consisting of GI paediatricians, radiologists, nutritionists, surgeons, nurses and adult gastroenterologists. Once the diagnosis was confirmed, the patients were followed up at the outpatient department regularly, and some patients were admitted to hospital for further treatment if necessary. A well-trained administrative staff was assigned to collect, document and store all the data.

There were 200 patients primarily reviewed. Fourteen diagnosed as having IBD-U could not be precisely classified until final follow-up and were therefore excluded from this study. Thirty-two patients with a follow-up period of less than 6 months were also excluded; however, the 11 patients who died within 6 months after diagnosis were included. Another 11 patients with incomplete medical records or without reports of endoscopy or imaging examination were excluded as well. Finally, there were 143 patients included in this study. All were less than 17 years old at the time of diagnosis. The patients were classified into three groups according to their age at diagnosis: 0–2, 3–9 and 10–16 years old groups. Clinical information and laboratory tests were collected at diagnosis and at each follow-up.

Genetic workup

Twenty-four patients with onset before 3 years old had a genetic test (20 in the 0–2 y group and 4 in the 3–10 y group). Thirteen patients were involved in a previously published study that tested for 10 genes [13]; three of these had subsequent whole exome sequencing (WES). The other 10 patients with VEO-IBD were further suggested to undertake genetic tests, comprising of more than 50 genes [14, 15] that were closely related to VEO-IBD (medical exome sequencing). In addition, parents were verified by Sanger sequencing if any positive finding was detected in the IBD children. One 5-year-old patient was confirmed as having glycogen storage disease (GSD) Ib prior to IBD diagnosis.

Disease activity index and definition of other evaluation indexes

Disease activity was assessed by the Paediatric Crohn’s Disease Activity Index (PCDAI) for patients with CD [16], and the Paediatric Ulcerative Colitis Activity Index (PUCAI) for patients with UC [17]. Patients with PUCAI ≥65 were classified as having severe disease according to the Paris classification. In terms of disease progression, the duration between diagnosis and first relapse after clinical remission was recorded for each patient. A patient was defined as being in clinical remission if the disease activity index was < 10 after induction therapy until the last follow-up, whereas a patient was defined as not in remission or relapse if the disease activity index was ≥10 with symptoms after induction therapy. Steroid dependency was defined as a patient receiving more than 10 mg/d prednisolone for more than 3 months or clinical relapses were seen within 3 months of tapering steroids. Patients starting biological agents early after diagnosis were regarded as receiving “top-down” treatment.

Growth and developmental index

Height and weight were two important factors that were routinely recorded at primary diagnosis as well as at subsequent follow-up examinations in order to monitor physical growth and development; the index score was calculated by the Z-scoring method based on the national survey on growth of children under 7 years of age in nine cities of China in 2005 [18]. Z < − 2 for weight at primary diagnosis and follow-up examination was recorded, and growth impairment (G1) was defined by the criteria of the Paris classification [6].

Statistical analysis

Discrete variables are expressed as numbers and percentages. Quantitative variables of normal distribution were expressed as the mean ± standard deviation (SD). Data was analysed by t-test and chi-squared test to compare categorical data between different age groups. Quantitative variables of skewed distribution were expressed as median and interquartile range and compared by Kruskal-Wallis Wilcoxon rank sum test. Differences were considered statistically significant at P < 0.05. Risk factors for surgery, death, and relapse were measured using Cox proportional hazard models for clustered data. Age group, gender, location and behaviour, nutrition status and treatment were included, and factors with a P < 0.05 in univariate analysis were included in multivariate marginal Cox proportional hazard regression to create the adjusted model and their corresponding hazard ratio (HR) and 95% CI (confidence interval). Cumulative probabilities of death, surgery and relapse rate in various age groups were calculated using the Kaplan–Meier method. SPSS 19 (Chicago, IL) was used for statistical analyses. GraphPad Prism 5 was used for Kaplan-Meier pictures.

Results

Patient characteristics

A total of 143 IBD patients (113 CD and 30 UC) aged under 17 years old were followed for a total of 404.08 person-years with a median follow-up duration of 26 months (range, 0–175 months). The median age at diagnosis was 9 years old. The youngest patient was 2 months old and the oldest was 16 years old. A total of 119 (83.2%) patients were from other provinces (19 provinces) and 64 (44.8%) patients were referred from other hospitals. There were 14 patients confirmed to have monogenic diseases and 13 of these had IL-10 receptor A (IL-10 RA) defects; they were all younger than 3 years old at the time of diagnosis. The mutations of four patients were homozygous, while the others were compound heterozygotes. Eight mutation sites were found; according to the guidelines for the interpretation of sequence variants by the ACMG (American College of Medical Genetics) [19], six sites were classified as pathogenic (p.R101W, p.T179 T, p.R117H, p.G141R, p.W424X and p.R165X) and two were classified into likely pathogenic (p.V100G and p.Y64C). One five-year-old patient was diagnosed as having GSD Ib (compound heterozygote of SLC37A4, two pathogenic sites) prior to IBD diagnosis. Family history of IBD was identified in six patients, and four of these had IL-10 RA defects. No consanguinity of parents was found in any patient.

Clinical manifestations

Table 1 shows the clinical manifestations of all groups of patients with three different ages. The findings indicated that clinical manifestations varied according to age. The percentage of diarrhoea and blood in stool were relatively high in the 0–2 y group. Other systemic complications, including fever (73.5%), anaemia (76.5%), and growth impairment (55.9%) were also commonly found in this group.
Table 1

Patient characteristics and clinical manifestations at diagnosis of different age groups

Characteristics

0–2 y

3–9 y

10–16 y

P value

Number (%)

34 (23.8)

46 (32.2)

63 (44.0)

 

Male sex, n (%)

24 (70.6)

28 (60.9)

37 (58.7)

0.50

Diagnosis CD, n (%)

30 (88.2)

31 (67.4)

52 (82.5)

0.05

Genetics disease, n (%)

13 (38.2)

1 (2.2)

0 (0.0)

< 0.01

Family history of IBD, n (%)

5 (14.7)

1 (2.2)

0 (0.0)

< 0.01

Median time from symptom onset to diagnosis, mo (IQR)

5 (9.3)

4 (10.3)

4.5 (8.0)

0.41

Median duration of follow-up period, mo (IQR)

9 (22.3)

38 (45.0)

31 (46.0)

< 0.01

Symptoms n (%)

 Abdominal pain

N/Aa

35 (76.1)

49 (77.8)

0.84

 Diarrhoea

32 (94.1)

36 (78.3)

38 (60.3)

< 0.01

 Blood in stool

26 (76.5)

30 (65.2)

30 (47.6)

0.02

 Oral ulcer

7 (20.6)

5 (10.9)

13 (20.6)

0.36

 Fever

25 (73.5)

21 (45.7)

21 (33.3)

< 0.01

 Anaemia

26 (76.5)

30 (65.2)

41 (65.1)

0.47

 weight < -2SD

16 (47.1)

8 (17.4)

10 (15.9)

< 0.01

 Growth impairment

19 (55.9)

18 (39.1)

13 (20.6)

< 0.01

 limitation of activities

17 (50)

13 (28.3)

14 (22.2)

< 0.01

 Joints

0 (0)

5 (10.9)

1 (1.6)

0.02

 Skin

2 (5.9)

1 (2.2)

1 (1.6)

0.50

aAs the presence of abdominal pain in younger children is very difficult to identify, we did not calculate the numbers of 0–2 y group and only compared the other two groups

Classification and location of the disease

Paris classification of UC and CD at diagnosis is shown in Table 2. The location of CD varied according to age. The lesions were located mainly in L2 (colonic) in the 0–2 y group; lesions were located mainly in L3 (ileocolonic) in groups 3–9 y and 10–16 y. Thirty-five of 113 (31.0%) CD patients showed upper GI tract lesions based on macroscopic appearance of mucosal ulceration or bowel wall thickening on radiography, and there was one 16-year-old patient with an upper GI lesion only, without colonic or ileocaecal lesions. The behaviour of disease also differed amongst groups. The 0–2 y group showed such lesions as B2 or B2B3 at relatively high percentages. The disease activity was higher in the 0–2 y group than in others at the time of diagnosis.
Table 2

Paris phenotype and disease activity at diagnosis of different age groups

 

0–2 y

3–9 y

10–16 y

P value

UC disease extent, n (%)

 E1 proctitis

0 (0)

2 (13.3)

1 (9.1)

0.80

 E2 left-sided colitis

1 (25.0)

5 (33.4)

3 (27.3)

 

 E3 extensive colitis

2 (50.0)

2 (13.3)

2 (18.2)

 

 E4 pancolitis

1 (25.0)

6 (40.0)

5 (45.4)

 

 severe (PUCAI≥65)

0 (0)

3 (20.0)

3 (27.3)

0.35

CD disease location, n (%)

 L1: terminal ileum

2 (6.7)

4 (12.9)

12 (23.1)

< 0.01

 L2: colonic

20 (66.6)

5 (16.1)

6 (11.5)

 

 L3: ileocolonic

8 (26.7)

22 (71.0)

33 (63.5)

 

Upper gastrointestinal, n (%)

 L4a + b:

0

0

7 (13.5)

0.03

 L4a

4 (13.3)

8 (25.8)

13 (25.0)

 

 L4b

1 (3.3)

1 (3.2)

1 (1.9)

 

CD disease behaviour, n (%)

 B1: non-stricturing, non-penetrating

10 (33.3)

15 (48.4)

23 (44.2)

0.04

 B2: stricturing

13 (43.3)

8 (25.8)

27 (51.9)

 

 B3: penetrating

5 (16.7)

7 (22.6)

1 (1.9)

 

 B2B3: stricturing and/or penetrating

2 (6.7)

1 (3.2)

1 (1.9)

 

 P: perianal

23 (76.7)

6 (19.4)

19 (36.5)

< 0.01

Disease activity (at the diagnosis)

 PCDAI (mean ± SD)

50.9 ± 12.3

40.0 ± 11.9

35.4 ± 12.4

< 0.01

 PUCAI (mean ± SD)

31.3 ± 16.5

44.0 ± 18.4

44.1 ± 20.0

0.46

Medical treatment

The treatment of IBD followed a standardized protocol for patients according to the guidelines as described [20, 21]. Induction therapy and maintenance therapy of the first year is displayed in Table 3. Two infantile patients after colectomy and colostomy were remission with total enteral nutrition (TEN). The patients with GSD Ib were treated with granulocyte colony-stimulating factor (G-CSF) and mesalazine. Forty-two (29.4%) patients were steroid-dependent. Most patients received antibiotics as necessary during the course. Supportive treatments, including parenteral or enteral nutrition, immune globulin, albumin, transfusion with concentrated red cells, were given as necessary.
Table 3

Main medical treatment of CD and UC

Treatment

Number of patients (%)

CD (n = 113)

UC (n = 30)

IBD (n = 143)

Induction therapy

 Corticosteroids

57 (50.4)

18 (60.0)

75 (52.4)

 Mesalazine

29 (25.7)

25 (83.3)

54 (37.8)

 Biological agent

65 (45.5)

5 (16.7)

70 (49.0)

 Thalidomide

14 (12.4)

3 (10.0)

17 (11.9)

Maintenance therapya

 Azathioprine

54 (47.8)

6 (20.0)

60 (42.0)

 Biological agent

48 (42.5)

2 (6.7)

50 (35.0)

 Thalidomide

32 (28.3)

3 (10.0)

35 (24.5)

 Mesalazine

23 (20.4)

21 (70.0)

44 (30.8)

 Methotrexate

3 (2.7)

0

3 (2.1)

 Cyclosporine A

2 (1.8)

0 (0.0)

2 (1.4)

 Total enteral nutrition

2 (1.8)

0 (0.0)

2 (1.4)

 Corticosteroids

31 (27.4)

11 (36.7)

42 (29.4)

aThe data are from an analysis of the first year of maintenance therapy

Surgical treatment

There were 15 (10.5%) patients who underwent abdominal surgeries, including 14 CD patients and 1 UC patient. The surgeries were carried out in the median duration of 5 months after disease onset; 14/15 patients underwent surgery within 20 months, and the remaining patient had surgery at 190 months. Figure 1 shows the Kaplan–Meier curve of time from onset to colectomy within 10 years. There were three major indications: confirmed diagnosis with exploratory laparotomy (3/15, 20.0%), intestinal perforation surgery (7/15, 46.7%) and aggressive disease after medical treatment (5/15, 33.3%). Cox univariate analysis showed that surgery was only associated with B3 behaviour (HR: 10.2; 95% CI: 3.35–31.36; P < 0.01). Intestinal or ileocaecal segment resection was performed in all patients; 9/15 patients underwent colostomy or ileostomy simultaneously. Up to the latest follow-up, one patient with perforation died after surgery; one patient who underwent re-anastomosis of the bowel 5 months after colostomy died of sepsis after relapse. One patient had persistent disease activity after reconnection of the bowels. Six patients went into remission after colostomy, including two patients with TEN and others with medical therapy. The others were managed with medical treatment after surgery.
Fig. 1
Fig. 1

Kaplan-Meier curve of time from onset to colectomy within 10 years follow-up

Death analysis

Seventeen patients (11.9%) died, all of whom were CD patients. The characteristics of these patients are listed in Table 4. The median diagnosis age was 1 year old (range, 0.16–5 years old). The median time from diagnosis to death was 3.7 months (range, 0.4–43.7 months). Fourteen patients died of various complications of CD, the majority from serious infections such as sepsis, while one patient died of sepsis after UCBT. Three died of intestinal perforation with or without surgery. Cox univariate analysis showed that the death of CD patients was associated with age, perianal disease, B3 behaviour and z-value of weight < − 2 (P < 0.01). Further multivariate analysis clearly suggested that age 0–2 y and B3 behaviour were risk factors for death (Table 5). Figure 2 shows the cumulative survival rates of various age groups. There was no difference in mortality between patients with or without gene mutations in the 0–2 y group.
Table 4

Characteristics and clinical manifestations of patients who died

No.

Genetic Test

Age of diagnosis (y)

Initial presentation

Phenotype

Family history

Medication

Surgery

Cause of death

Months from diagnosis to death

Year of death

1

NA

3

Abdominal pain, fever

B3 + P

None

CS

Colectomy and enterostomy

Intestinal perforation

3.2

2007

2

NA

2.3

Diarrhoea, Blood in stool

B2

None

CS

Infection

1.5

2007

3

NA

5

Diarrhoea

B3 + P

None

CS, MES

Infection

11.2

2009

4

NA

0.6

Diarrhoea

B1 + P

None

IFX, CS

Infection

4.2

2010

5

NA

2

Diarrhoea

B2 + P

A brother died of diarrhoea

IFX, CS

Enterostomy

Infection

5.0

2011

6

NA

1

Diarrhoea

B2B3 + P, L4a

None

CS

Infection

0.6

2011

7

NA

1.5

Diarrhoea, fever

B2 + P

None

CS, AZA

Infection

43.7

2015

8

NA

0.3

Diarrhoea, fever

B3 + P

None

CS

Infection

2.0

2012

9

ND

1.5

Diarrhoea, fever

B2 + P

None

IFX, CS, THD

Intestinal perforation

26.3

2014

10

IL-10RA

0.83

Diarrhoea, fever

B1 + P

None

IFX, CS, THD

Infection

6.1

2014

11

NA

0.83

Diarrhoea, fever

B2B3 + P, L4b

None

CS

Intestinal perforation

0.5

2014

12

NA

0.16

Diarrhoea, fever

B3 + P

None

CS

Infection

2.1

2015

13

ND

2.5

Diarrhoea, fever

B2 + P

None

IFX, CS

Infection

3.7

2014

14

IL-10RA

0.8

Diarrhoea, fever

B3 + P

No.17’s sister

THD

Infection

1.6

2014

15

ND

1

Diarrhoea, fever

B2 + P

None

CS

Infection

10.4

2016

16

IL-10RA

1.67

Diarrhoea, fever

B1 + P, L4a

None

Antibiotics onlya

Infection

0.4

2016

17

IL-10RA

0.58

Diarrhoea, fever

B1

No 14’s younger brother

UCBT

Infection after UCBT

9.5

2016

AZA azathioprine, CS corticosteroids, EN enteral nutrition, IFX infliximab, MES mesalazine, NA not available, THD thalidomide, ND not detected, UCBT umbilical cord blood trans-plantation

aOther patients may also use antibiotics but not list in the table

Table 5

Univariable and multivariable analyses of clinical variables influencing death in CD

Variables

Univariable analysis

Multivariable analysis (significant in univariate)

HR

95% CI

P value

HR

95% CI

P value

Age

 3–9 y vs 0–2 y

0.09

0.02–0.38

< 0.01

0.11

0.18–0.61

0.01

 10–16 y vs 0–2 y

0.01

0.00–0.00

0.93

0

0–0

0.92

Sex

 female vs male

0.35

0.10–1.22

0.10

   

Disease location

 L2 vs L1

7.15

0.92–55.37

0.06

   

 L3 vs L1

1.40

0.16–11.94

0.76

   

 L4 vs no L4

0.48

0.14–1.68

0.25

   

 Perianal disease vs not

12.37

2.81–54.80

< 0.01

3.45

0.69–17.28

0.13

 Behaviour B2 vs not

1.02

0.39–2.64

0.97

   

 Behaviour B3 vs not

5.23

1.98–13.79

< 0.01

4.83

1.57–14.87

< 0.01

 Weight < -2SD vs not

5.96

2.20–16.20

< 0.01

1.51

0.51–4.52

0.46

 Growth impairment vs not

2.01

0.77–5.29

0.16

   

 Top-down treatment vs not

0.40

0.09–1.74

0.22

   

 Steroid dependency vs not

1.75

0.67–4.60

0.26

   
Fig. 2
Fig. 2

Kaplan-Meier curves showing time from diagnosis to death. Log rank test for equality of survival curves, P < 0.01

Relationship between sustained remission and phenotype of the disease

Based on follow-up data, there were 52 (36.4%) patients achieving sustained remission. There were 34 (23.8%) patients with persistent index activity after the first three-month treatment. Fifty-seven (39.8%) patients relapsed, and 27 (47.6%) of these relapsed within 1 year of diagnosis. The cumulative sustained remission rates are shown in Fig. 3. The remission varied amongst the age groups. Cox univariate analysis indicated that the relapse of CD was associated with age, perianal disease, B3 behaviour, z-value of weight < − 2 and steroid dependency. Further multivariate analysis suggested that age group 0–2 y, B3 behaviour and steroid dependency were risk factors (Table 6). There was no difference of remission between patients with or without gene mutations in the 0–2 y group.
Fig. 3
Fig. 3

Kaplan-Meier curves showing time from diagnosis to relapse. Log rank test for equality of survival curves, P < 0.01

Table 6

Univariable and multivariable analyses of clinical variables influencing relapse in CD

Variables

Univariable analysis

Multivariable analysis (significant in univariate)

HR

95% CI

P value

HR

95% CI

P value

Age

 3–9 y vs 0–2 y

0.25

0.14–0.48

< 0.01

0.26

0.13–0.53

< 0.01

 10–16 y vs 0–2 y

0.20

0.11–0.36

< 0.01

0.23

0.12–0.44

< 0.01

Sex

 female vs male

0.84

0.52–1.36

0.47

   

Disease location

 L2 vs L1

2.18

0.98–4.84

0.06

   

 L3 vs L1

1.29

0.61–2.77

0.51

   

 L4 vs no L4

0.89

0.54–1.46

0.64

   

 Perianal disease, yes vs no

1.59

1.00–2.53

0.048

1.13

0.68–1.88

0.63

 Behaviour B2 vs not

1.04

0.66–1.64

0.87

   

 Behaviour B3 vs not

2.08

1.15–3.77

0.02

1.96

1.01–3.81

0.046

 Weight < -2SD vs not

1.71

1.04–2.82

0.04

0.96

0.54–1.69

0.88

 Growth impairment vs not

1.31

0. 83–2.09

0.25

   

 Top-down treatment vs not

0.69

0.40–1.21

0.20

   

 Steroid dependency vs not

2.26

1.40–3.64

< 0.01

1.88

1.16–3.06

0.01

Discussion

In this study, we analysed the relationship between disease phenotype and prognosis of paediatric inflammatory bowel disease in China. Younger patients may have extensive and aggressive disease. In the present study, 56% of paediatric IBD patients were younger than 10 years and 23.8% patients were younger than 3 years old. By contrast, the rate was quite low in a study carried out in Italy in which the VEO-IBD (0–3 y) was only 4%; however, the fundamental difference was that patients with genetic defects were excluded [22]. In addition, the proportion of patients younger than 10 years old were also higher than in other studies (23.2–50%) [2225]. The explanation may be that, as a hospital specializing in refractory IBD, we observed more refractory patients who were recruited for this study and the patients recruited were much younger.

DNA sequencing tests for VEO-IBD patients were performed in the current study since 2012, and we found that 58.3% of the tested patients had monogenetic disorders with the gene mutation on IL-10 receptor A (IL-10RA). Glocker et al. first reported in 2009 that the mutation of IL-10 receptor caused IBD [26]; since then, IL-10 receptor defects have drawn much attention by paediatric IBD researchers worldwide [27, 28]. It is interesting that most studies in East Asia including our results pointed out the dominance of IL-10RA mutations in IBD patients. By contrast, based on the European data, the numbers of patients with IL-10RA and IL-10 receptor B (IL-10RB) mutation were somewhat equivalent. In addition, our data demonstrated that none of our patients suffered from lymphoma and no parents were consanguineous; these observations are also different from those of the European survey [28]. Because of the high percentage of positive findings, one would speculate that there should be more patients with gene mutations related to IBD in those diagnosed before 2012 who were not examined by the NGS test. Furthermore, some studies demonstrated that many monogenetic disorders may cause IBD [29]. We had a patient who developed IBD secondary to GSD Ib, something that has not been reported in China before. It is noteworthy that 77% of GSD Ib patients may have IBD, and for these patients, recommended treatment is with G-CSF and mesalazine rather than with steroids [30, 31]. We also diagnosed two younger patients with diarrhoea as having chronic granulomatous disease (CYBB mutation) and hyper-IgM syndrome (CD40LG mutation). Both of which have been reported as monogenetic disorders causing IBD. Since they did not have typical IBD endoscopic and pathological manifestations, these two patients were not included in the study. Another study also reported mutations in EPCAM, TNFAIP3 and LRBA in China. However, based on all the data, it has been confirmed that IL-10 RA may be the main mutation in China [32, 33].

The clinical manifestations and phenotypes of diseases were analysed for patients diagnosed in the current study. Patients in the 0–2 y group commonly manifested systemic symptoms such as fever, weight loss and limitation of activity, colonic lesions, strictures and perianal disease; this was similar to what was reported in other studies [34]. It was reported that patients usually had accompanying extra-intestinal symptoms of joints, skin, liver, and eyes with percentages as high as 10–20% [23, 35]; however, few patients in the current study developed these extra-intestinal symptoms. It is worth noting that there were two patients with histories of juvenile rheumatoid arthritis (JIA) in the study; further investigation is needed to elucidate whether JIA and IBD are associated with the same pathogenesis.

Our centre has a standardized protocol of treatments for IBD patients. Of the total, 76.2% went into remission or improved after induction therapy. However, patients younger than 3 years old may relapse or suffer from various complications, possibly leading to a poor prognosis. Our findings indicated that infantile patients, penetrating lesions and steroid dependency were risk factors for poor prognosis, a finding that accorded with the consensus guidelines of ECCO/ESPGHAN [20].

Death reports were relatively high in this study, and all the deaths were in patients < 6 years old with CD. Most of these were very sick when they were recruited at the centre and half of them died within the first 3 months after diagnosis. Some patients responded to the treatment of IBD but developed infections and died unexpectedly. Some deaths were confirmed as being associated with IL-10RA defects. It was reported that IL-10RA mutations affected immune function, and patients with IL-10RA mutations may have a poorer prognosis [13]. Fortunately, IL-10RA and IL-10RB mutations can now be cured through haematopoietic stem cell transplantation [9, 36].

Based on our follow-up data, patients with a poor response to medicine would improve after colectomy, especially combined with colostomy. It was reported that all patients with IL-10RA and IL-10RB mutations need surgical interventions, including partial or subtotal colectomy. This may prolong survival time, but cannot help patients achieve remission [37]. Our experience showed that colostomy might be an effective therapy that can maintain clinical remission but cannot lead to mucosal healing. As some patients refused to have colostomy when advised, the reported percentage of surgery may be lower than medically necessary. Because a limited number of patients had long follow-up of colostomy, more clinical observation is required.

Our results have some limitations. As a hospital specializing in refractory IBD, the clinical features of patients presenting with refractory IBD differ from those of the general population. This may cause referral bias. A national IBD network should be set up to recruit more patients within the Chinese population. Another limitation was that, as a retrospective study, non-standardized documentation may have resulted in the inability to determine disease prognosis with various treatments. Furthermore, antibiotics and supportive treatment including parenteral or enteral nutrition were not recorded in detail. The potential variability in treatment practices could impact outcomes. It is worthwhile to set up a randomized controlled trial to analyse the long-term efficacy and safety of these medicines in different age groups. It is worth noting that the development of diagnostic methods during our study period may have affected the evaluation and treatments in the study. For example, genetic testing may have impacted the rate of detection of monogenic disease and changes in investigations (MRE and capsule endoscopy) over the study period, possibly impacting determination of the extent of small bowel Crohn’s disease.

Conclusions

We determined that age was the major factor determining the various clinical manifestations and prognoses for IBD patients. Infantile IBD may be caused by monogenic defects, particularly IL-10 RA mutations. Colostomy can improve clinical symptoms, but haematopoietic stem cell transplantation might cure these patients. NGS should be performed for each VEO-IBD, especially for infants. It is necessary to incorporate genetic testing into medical insurance plans and to regard it as a routine examination. This will improve the diagnosis and treatment of VEO-IBD in China.

Abbreviations

ACMG: 

American College of Medical Genetics

AZA: 

Azathioprine

CD: 

Crohn’s disease

CI: 

Confidence interval

CS: 

Corticosteroids

EN: 

Enteral nutrition

ESR: 

Erythrocyte sedimentation rate

G-CSF: 

Granulocyte colony-stimulating factor

GI: 

Gastrointestinal

GSD: 

Glycogen storage disease

HR: 

Hazard ratio

IBD: 

Inflammatory bowel disease

IBD-U: 

IBD-unclassified

IFX: 

Infliximab

IL-10 RA: 

IL-10 receptor A

IL-10RB: 

IL-10 receptor B

IQR: 

Interquartile range

JIA: 

Juvenile rheumatoid arthritis

MDT: 

Multi-disciplinary team

MES: 

Mesalazine

MTX: 

Methotrexate

NA: 

Not available

ND: 

Not detected

NGS: 

Next generation sequencing

PCDAI: 

Paediatric Crohn’s Disease Activity Index

PUCAI: 

Paediatric Ulcerative Colitis Activity Index

SD: 

Standard deviation

TEN: 

Total enteral nutrition

THD: 

Thalidomide

UC: 

Ulcerative colitis

UCBT: 

Umbilical cord blood trans-plantation

VEO-IBD: 

Very early onset IBD

WES: 

Whole exome sequencing

y: 

Years

Declarations

Acknowledgements

We are grateful to our colleagues in the Department of Paediatrics, Ruijin Hospital, Ruijin Hospital North for their help with the study. We thank Prof. Hong-hua Mu and Cornnor Meaney for their English language editing. We thank all authors who have read and approved the final manuscript.

Funding

This work was supported by National Nature Science Foundation of China under Grant No. 81400588 and IPSEN Fund for the research of diarrhoea under Grant No. IDF-2015-02.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WXQ, XCD and YYZ designed this study; WXQ and XX drafted the manuscript. XY performed next generation sequencing; YY, SCY, GY, XX and GL collected and interpreted the data; ZT, WXJ and GSS statistically analysed the data. All authors have read and approved the final version to be published.

Ethics approval and consent to participate

The study was reviewed and approved by the ethics committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Verbal and written consent was obtained from parents or legal guardians of the patients at diagnosis or follow-up.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Paediatrics, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, No. 197, Rui Jin Er Road, Shanghai, 200025, China
(2)
Department of Paediatrics, Ruijin Hospital North, Shanghai Jiao Tong University, School of Medicine, Shanghai, 201821, China
(3)
Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200025, China
(4)
Department of Biostatistics, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200025, China

References

  1. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135(4):1106–13.View ArticlePubMedGoogle Scholar
  2. Wang XQ, Zhang Y, Xu CD, Jiang LR, Huang Y, Du HM, Wang XJ. Inflammatory bowel disease in Chinese children: a multicenter analysis over a decade from Shanghai. Inflamm Bowel Dis. 2013;19(2):423–8.View ArticlePubMedGoogle Scholar
  3. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135(4):1114–22.View ArticlePubMedGoogle Scholar
  4. Kugathasan S, Cohen S. Searching for new clues in inflammatory bowel disease: tell tales from pediatric IBD natural history studies. Gastroenterology. 2008;135(4):1038–41.View ArticlePubMedGoogle Scholar
  5. Maisawa S, Sasaki M, Ida S, Uchida K, Kagimoto S, Shimizu T, Yoden A. Characteristics of inflammatory bowel disease with an onset before eight years of age: a multicenter epidemiological survey in Japan. J Gastroenterol Hepatol. 2013;28(3):499–504.View ArticlePubMedGoogle Scholar
  6. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–21.View ArticlePubMedGoogle Scholar
  7. Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroenterol. 2015;21(43):12296–310.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, Hugot JP, Daussy C, Verkarre V, Pigneur B, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011;106(8):1544–55.View ArticlePubMedGoogle Scholar
  9. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147(5):990–1007. e1003View ArticlePubMedPubMed CentralGoogle Scholar
  10. Okou DT, Kugathasan S. Role of genetics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1878–84.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806.PubMedGoogle Scholar
  12. Ibd Working Group of the European Society for Paediatric Gastroenterology H, Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41(1):1–7.View ArticleGoogle Scholar
  13. Xiao Y, Wang XQ, Yu Y, Guo Y, Xu X, Gong L, Zhou T, Li XQ, Xu CD. Comprehensive mutation screening for 10 genes in Chinese patients suffering very early onset inflammatory bowel disease. World J Gastroenterol. 2016;22(24):5578–88.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, et al. Variants in TRIM22 that affect NOD2 signaling are associated with very-early-onset inflammatory bowel disease. Gastroenterology. 2016;150(5):1196–207.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Uhlig HH, Schwerd T. From genes to mechanisms: the expanding spectrum of monogenic disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):202–12.View ArticlePubMedGoogle Scholar
  16. Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41(4):416–21.View ArticlePubMedGoogle Scholar
  17. Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, Pfefferkorn M, Rosh J, Kay M, Crandall W, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15(8):1218–23.View ArticlePubMedGoogle Scholar
  18. Coordinating Study Group of Nine Cities on Physical G, Development of C, Capital Institute of P. A national survey on growth of children under 7 years of age in nine cities of China, 2005. Zhonghua Er Ke Za Zhi. 2007;45(8):609–14.Google Scholar
  19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8(10):1179–207.View ArticlePubMedGoogle Scholar
  21. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H, Ibd Working Group of the British Society of Paediatric Gastroenterology H, Nutrition. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010;50(Suppl 1):S1–13.View ArticlePubMedGoogle Scholar
  22. Aloi M, Lionetti P, Barabino A, Guariso G, Costa S, Fontana M, Romano C, Lombardi G, Miele E, Alvisi P, et al. Phenotype and disease course of early-onset pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(4):597–605.View ArticlePubMedGoogle Scholar
  23. Buderus S, Scholz D, Behrens R, Classen M, De Laffolie J, Keller KM, Zimmer KP, Koletzko S, Group C-GS. Inflammatory bowel disease in pediatric patients: characteristics of newly diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int. 2015;112(8):121–7.PubMedPubMed CentralGoogle Scholar
  24. Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, Gold BD, Winter HS, Baldassano RN, Smith T, et al. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 2008;103(8):2092–8.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Zhu L, Shi T, Zhong C, Wang Y, Chang M, Liu X. IL-10 and IL-10 receptor mutations in very early onset inflammatory bowel disease. Gastroenterology Res. 2017;10(2):65–9.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–45.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci. 2011;1246:102–7.View ArticlePubMedGoogle Scholar
  28. Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, Guariso G, Canioni D, Lambot K, Talbotec C, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013;19(13):2820–8.View ArticlePubMedGoogle Scholar
  29. Christodoulou K, Wiskin AE, Gibson J, Tapper W, Willis C, Afzal NA, Upstill-Goddard R, Holloway JW, Simpson MA, Beattie RM, et al. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. Gut. 2013;62(7):977–84.View ArticlePubMedGoogle Scholar
  30. Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GP. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr. 2000;137(2):187–91.View ArticlePubMedGoogle Scholar
  31. Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr. 2002;161(Suppl 1):S88–92.View ArticlePubMedGoogle Scholar
  32. Huang Z, Peng K, Li X, Zhao R, You J, Cheng X, Wang Z, Wang Y, Wu B, Wang H, et al. Mutations in Interleukin-10 receptor and clinical phenotypes in patients with very early onset inflammatory bowel disease: a Chinese VEO-IBD collaboration group survey. Inflamm Bowel Dis. 2017;23(4):578–90.View ArticlePubMedGoogle Scholar
  33. Ye Z, Zhou Y, Huang Y, Wang Y, Lu J, Tang Z, Miao S, Dong K, Jiang Z. Phenotype and Management of Infantile-onset Inflammatory Bowel Disease: experience from a tertiary Care Center in China. Inflamm Bowel Dis. 2017;23(12):2154–64.View ArticlePubMedGoogle Scholar
  34. Nambu R, Hagiwara S, Kubota M, Kagimoto S. Difference between early onset and late-onset pediatric ulcerative colitis. Pediatr Int. 2016;58(9):862–6.View ArticlePubMedGoogle Scholar
  35. Urlep D, Trop TK, Blagus R, Orel R. Incidence and phenotypic characteristics of pediatric IBD in northeastern Slovenia, 2002-2010. J Pediatr Gastroenterol Nutr. 2014;58(3):325–32.View ArticlePubMedGoogle Scholar
  36. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62(12):1795–805.View ArticlePubMedGoogle Scholar
  37. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R, Elawad M, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131(3):825–30.View ArticlePubMedGoogle Scholar

Copyright

Advertisement